SLC29A1 and neoplasm: For gemcitabine, tumor expression of the human equilibrative nucleoside transporter (hENT1) seems to be associated with the increased efficacy of this drug [20–22], yet the prognostic value of this biomarker remains controversial and has been mainly assessed in an adjuvant setting [23–25].